摘要
目的度洛西汀和黛力新治疗躯体化障碍的有效性、安全性及对患者生活质量的影响。方法将120例躯体化障碍患者按随机数字法分为度洛西汀组(60例)和黛力新组(60例)。治疗前2周,两组均口服劳拉西泮,在此基础上度洛西汀组口服度洛西汀治疗,黛力新组口服黛力新治疗,观察8周。统计并比较两组的临床疗效及不良发应发生率,于治疗前后采用躯体症状自评量表、汉密顿焦虑量表、汉密顿抑郁量表、世界卫生组织生存质量评定量表评定躯体症状、焦虑症状、抑郁症状及生活质量。结果两组总有效率比较差异无统计学意义(P>0.05)。治疗前两组各量表评分比较差异无统计学意义(P>0.05);治疗后两组躯体症状自评量表、汉密顿焦虑量表、汉密顿抑郁量表评分均较治疗前显著下降(P<0.01),世界卫生组织生存质量评定量表评分均较治疗前显著上升(P<0.01),度洛西汀组显著优于黛力新组(P<0.01)。度洛西汀组不良反应发生率显著低于黛力新组(P<0.05)。结论度洛西汀与黛力新治疗躯体化障碍疗效均显著,度洛西汀在改善躯体症状、焦虑抑郁症状及提高生活质量方面效果更好,安全性更高。
Objective To evaluate the efficacy,safety and impact on the life quality of duloxetine and deanxit in the treatment of somatization disorder.Methods 120 patients with somatization disorder were randomly divided into duloxetine group(60 cases)and deanxit group(60 cases).Two weeks before treatment,both groups were treated with lorazepam.On the basis of this,the duloxetine group was treated with oral duloxetine,and the deanxit group was treated with deanxit and treated for 8 weeks.Compare the clinical efficacy and incidence of adverse reactions between the two groups.Somatic symptoms,anxiety symptoms,depressive symptoms and quality of life were assessed before and after treatment using the Somatic Symptom Scale,the Hamilton Anxiety Scale,the Hamilton Depression Scale,and the WHOQOL.Results There was no significant difference in the total effective rate between the two groups(P>0.05).There was no significant difference in the scores of the scales between the two groups before treatment(P>0.05).After treatment,the scores of SSS,HAMA and HAMD were significantly lower than those before treatment(P<0.01).The WHOQOL scores were significantly higher than those before treatment(P<0.01).The duloxetine group was significantly better than the deanxit group(P<0.01).The incidence of adverse reactions was significantly lower in the duloxetine group than that in the deanxit group(P<0.05).Conclusion Duloxetine and deanxit are effective in the treatment of somatization disorder.Duloxetine is more effective and safer in improving physical symptoms,anxiety and depression,and improving quality of life.
作者
张映虹
李义会
刘继
Zhang Yinghong;Li Yihui;Liu Ji(Nanyang Psychiatric Hospital,Nanyang 473083,Henan,China)
出处
《临床心身疾病杂志》
CAS
2019年第3期138-140,共3页
Journal of Clinical Psychosomatic Diseases
关键词
躯体化障碍
度洛西汀
黛力新
临床疗效
生活质量
Somatization disorder
duloxetine
deanxit
clinical efficacy
quality of life